- Home
- TACT vs ACRV Comparison
TACT vs ACRV Comparison
Compare TACT & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TACT
- ACRV
- Stock Information
- Founded
- TACT 1996
- ACRV 2018
- Country
- TACT United States
- ACRV United States
- Employees
- TACT N/A
- ACRV N/A
- Industry
- TACT Computer peripheral equipment
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- TACT Technology
- ACRV Health Care
- Exchange
- TACT Nasdaq
- ACRV Nasdaq
- Market Cap
- TACT 51.0M
- ACRV 47.8M
- IPO Year
- TACT 1996
- ACRV 2022
- Fundamental
- Price
- TACT $4.66
- ACRV $1.92
- Analyst Decision
- TACT Strong Buy
- ACRV Buy
- Analyst Count
- TACT 1
- ACRV 6
- Target Price
- TACT $5.00
- ACRV $17.75
- AVG Volume (30 Days)
- TACT 51.9K
- ACRV 472.0K
- Earning Date
- TACT 11-06-2025
- ACRV 11-12-2025
- Dividend Yield
- TACT N/A
- ACRV N/A
- EPS Growth
- TACT N/A
- ACRV N/A
- EPS
- TACT N/A
- ACRV N/A
- Revenue
- TACT $47,949,000.00
- ACRV N/A
- Revenue This Year
- TACT $21.67
- ACRV N/A
- Revenue Next Year
- TACT $7.63
- ACRV $805.34
- P/E Ratio
- TACT N/A
- ACRV N/A
- Revenue Growth
- TACT N/A
- ACRV N/A
- 52 Week Low
- TACT $3.12
- ACRV $1.05
- 52 Week High
- TACT $5.70
- ACRV $8.74
- Technical
- Relative Strength Index (RSI)
- TACT 40.08
- ACRV 59.79
- Support Level
- TACT $4.53
- ACRV $1.80
- Resistance Level
- TACT $5.26
- ACRV $2.04
- Average True Range (ATR)
- TACT 0.34
- ACRV 0.14
- MACD
- TACT -0.12
- ACRV -0.01
- Stochastic Oscillator
- TACT 9.39
- ACRV 66.20
About TACT TransAct Technologies Incorporated
Transact Technologies Inc develops and sells software-driven technology and printing solutions. The company's software is sold under BOHA, AccuDate, Epic, EPICENTRAL, Ithaca, and Printrex brand names. It also provides supplies and consumables used in the printing and scanning activities to restaurant and hospitality, banking, retail, casino and gaming, point of sale automation, lottery, medical, mobile, oil, and gas markets. Majority of the revenue is derived from the casinos and gaming industry followed by the Foodservice technology market. Its geographical segments are the United States and International, of which the majority of its revenue comes from the United States.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.